
Avantor Inc. (AVTR) Stock Forecast & Price Target
Avantor Inc. (AVTR) Analyst Ratings
Bulls say
Avantor Inc. demonstrates a positive financial outlook, supported by expanding adjusted operating margins across its segments, with Life Sciences (LS) improving by 20 basis points to 13.1% and Bioprocessing (BP) increasing by 120 basis points to 26.6%. The company reported organic revenue growth of 1.0% to $1.69 billion in the fourth quarter, with the BP segment rebounding through high-single-digit growth driven by robust order intake and demand in bioprocessing, which is expected to continue into 2025. Additionally, Avantor's management anticipates ongoing margin expansion due to improvements in pricing, volume growth, cost-saving initiatives, and a favorable end-market exposure in healthcare, suggesting a potential for long-term financial improvements.
Bears say
Avantor Inc. faces a negative outlook due to a continued slowdown in purchasing from small biotech companies, which may lead to revenue declines in this segment. The company's diverse end markets exhibited inconsistencies, with education and government experiencing a modest decline, while growth in biopharma and healthcare was also lower than expected, affecting overall organic revenue. Additionally, prolonged inventory destocking at customer levels poses further risks to revenue guidance, compounded by negative impacts from foreign exchange and divestitures on the company's top-line performance.
This aggregate rating is based on analysts' research of Avantor Inc. and is not a guaranteed prediction by Public.com or investment advice.
Avantor Inc. (AVTR) Analyst Forecast & Price Prediction
Start investing in Avantor Inc. (AVTR)
Order type
Buy in
Order amount
Est. shares
0 shares